Barrier protective use of skin care to prevent chemotherapy-induced cutaneous symptoms and to maintain quality of life in patients with breast cancer

Figures & data

Figure 1 CONSORT diagram.

Abbreviations: SC, standard care; SC/TP, patient group that starts with SC followed by TP; TP, test preparation; TP/SC, patient group that starts with TP followed by SC; CONSORT, Consolidated Standards of Reporting Trials.

Table 1 Characteristics of study population

Characteristics	Group TP/SC		Group SC/TP		Total
	n	%	n	%	n	%
Total	36	49	37	51	73	100
Age, years
<30	1	1.37	0	0.00	1	1.37
30–40	1	1.37	5	6.85	6	8.22
41–50	11	15.07	13	17.81	24	32.88
51–60	9	12.33	12	16.44	21	28.77
61–70	10	13.70	5	6.85	15	20.55
71–80	4	5.48	2	2.74	6	8.22
Mean	6.0	8.2	6.2	8.4	12.2	16.7
SD	4.2	5.7	4.8	6.6	8.4	11.6
Chemotherapy
4× EC, 4× Doc	3	4.11	2	2.74	5	6.85
4× EC, 4× Doc,	1	1.37	0	0.00	1	1.37
Trastuzumab
3× FEC, 3× Doc	6	8.22	8	10.96	14	19.18
3× FEC, 3× Doc,	0	0.00	2	2.74	2	2.74
Trastuzumab
6× TAC	4	5.48	5	6.85	9	12.33
4× EC, 12× Pac	13	17.81	8	10.96	21	28.77
4× EC, 12× Pac,	5	6.85	5	6.85	10	13.70
Trastuzumab
4× FEC	0	0.00	1	1.37	1	1.37
6× FEC	1	1.37	3	4.11	4	5.48
6× TCbH	1	1.37	1	1.37	2	2.74
18× Pac + Dox	0	0.00	2	2.74	2	2.74
4× TC	1	1.37	0	0.00	1	1.37
Unknown	0	0.00	1	1.37	1	1.37

Abbreviations: Doc, docetaxel; Dox, doxorubicin; EC, epirubicin plus cyclophosphamide; FEC, 5-fluorouracil plus epirubicin plus cyclophosphamide; Pac, paclitaxel; SC, standard care; SC/TP, patient group that starts with SC followed by TP; SD, standard deviation; TAC, doxorubicin plus cyclophosphamide plus docetaxel; TC, taxane plus carboplatin; TCbH, taxane plus carboplatin plus trastuzumab; TP, test preparation; TP/SC, patient group that starts with TP followed by SC.

Figure 2 DLQI: comparison of both groups over application time.

Notes: (A) DLQI total, (B) DLQI SF. SC/TP group SC/TP group n=48; TP/SC group n=46. *Statistical significant difference between the groups, analysis of variance (P≤0.05).
Abbreviations: DLQI, Dermatology Life Quality Index;³⁵ SF, subscale Symptoms and Feelings.

Figure 3 VAS: comparison of both groups over application time.

Notes: (A) Pruritus, (B) skin dryness, (C) irritability. Standard care/test preparation group n=48; test preparation/standard care group n=46. *Statistical significant difference between the groups, analysis of variance (P≤0.05).
Abbreviation: VAS, visual analog scale.

FinlayAYKhanGKDermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical useClin Exp Dermatol1994192102168033378

 PubMed Web of Science ®Google Scholar